Artiva Biotherapeutics is a clinical-stage biotechnology company developing natural killer (NK) cell-based therapies for autoimmune diseases and cancers. Its lead product candidate, AlloNK (AB-101), is an allogeneic, non-genetically modified, cryopreserved NK cell therapy designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. The company is currently evaluating AlloNK in clinical trials for B-cell driven autoimmune diseases, prioritizing refractory rheumatoid arthritis as its lead indication, with plans to initiate a Phase 3 registrational trial. Artiva is also pursuing CAR-NK product candidates in multiple indications through collaborator-funded trials. The company holds ex-APAC rights to its programs and has received FDA Fast Track designation for rheumatoid arthritis and lupus nephritis.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage artivabio.com
Sector Healthcare IR page investors.artivabio.com/overview/default.aspx
Tags
cell therapy, natural killer cells, autoimmune diseases, rheumatoid arthritis, b-cell depletion, allogeneic therapy, clinical-stage, AlloNK, AB-101, B-cell Reset
Press page —

Metrics

Valuation  
Market cap $ 193.374M
Market cap (USD) $ 193.374M
P/E -1.31
PEG —
P/BV 0.60
P/S 770.42
P/OCF -2.29
P/FCF -2.23
Dividend yield —
Turnover / mcap —
Returns  
ROE -56.5%
ROI -92.0%
ROIC -73.9%
Profit margin —
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 14
Quality score -64.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Revenue 0 251K 33.492M 4.931M 2.002M
Net profit -83.865M -65.373M -32.766M -60.976M -71.825M
Free cash flow -79.338M -55.674M -50.688M -57.128M -17.028M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Share price 4.29 10.08 — — —
Price performance 12m -0.57 — — — —

Filed figures

Figure Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 1.03M 0.00 —
↳ YoY growth -100.0%
Lease liabilities (USD) — 16.9M 14.4M 10.9M
Cash and deposits (USD) 103M 53.5M 40.2M 26.7M
Right-of-use assets (USD) — 16.5M 13.8M 10.5M
Cash flow detail
Operating cash flow (USD) — -47.4M -55M -76.8M
Purchases of property, plant and equipment (USD) — -3.26M -642,000 -2.59M
Change in receivables (cash effect) (USD) — -510,000 1.03M 0.00
Change in payables (cash effect) (USD) — -408,000 519,000 -760,000
Income taxes paid (cash effect) (USD) — -83,000 0.00 —
Share-based compensation (USD) — 7.05M 6.98M 6.82M
Operating cash flow before change in receivables (USD) — -46.9M -56.1M -76.8M
Free cash flow (OCF - PPE - intangibles) (USD) — -50.7M -55.7M -79.3M
Income detail
Research and development expense (USD) — 50.3M 50.3M 69.5M
Total comprehensive income (USD) — -28.4M -65.8M -83.6M
Comprehensive income to owners (USD) — -28.4M -65.8M -83.6M
Reported Aug 29, 2024 Mar 24, 2025 Mar 24, 2025 Mar 10, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Resignation of Elizabeth Hougen as a Class III Director

On November 11, 2026, Elizabeth Hougen notified the Company of her decision to resign from the board of directors (the “Board”) of the Company as a Class III Director, effective immediately. Ms. Hougen’s resignation was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices.

Corporate Presentation

Artiva Corporate Presentation

Download (opens in new window)

Artivabio

Contact Us

5505 Morehouse Drive, Suite 100
San Diego, California 92121

1.858.267.4467

[email protected]

Twitter opens in a new window Linkedin opens in a new window

Quick Links

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Artiva Biotherapeutics, Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Artiva Biotherapeutics, Inc. to send you the requested Investor Email Alert updates.

* Required

Email Address *

Investor Alert OptionsInvestor Alert Options *

News
Events & Presentations
Quarterly Reports
Annual Reports
SEC Filings

Submit Submit

Unsubscribe

Email Alert Sign Up Confirmation

© 2026 Artiva Biotherapeutics, Inc.

Powered By Q4 Inc. 5.190.1.9 (opens in new window)

Upcoming & Recent Events

No events available right now. Please check back later.

Archived Events

Selecting a year value will change the event content

Select year:

202620252024

Date: September 24, 2026 Time: 7:00 AM PT

Stifel 2026 Virtual Immunology and Inflammation Forum Webcast

Date: September 14, 2026 Time: 2:30 PM ET

H.C. Wainwright 28th Annual Global Investment Conference

Virtual

Date: September 9, 2026 Time: 10:20 AM ET

2026 Cantor Global Healthcare Conference

Date: June 30, 2026 Time: 12:30 PM PT

H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Date: June 8, 2026 Time: 5:15 AM PT

Post-EULAR Virtual Webcast

Date: June 4, 2026 Time: 9:20 AM ET

2026 Jefferies Global Healthcare Conference in New York

Date: April 15, 2026 Time: 11:15 AM PT

25th Annual Needham Virtual Healthcare Conference

Date: March 4, 2026 Time: 1:10 PM ET

TD Cowen 46th Annual Health Care Conference

Showing page 1 of 3

  • 1
  • ...
  • 2
  • ...
  • 3

Scientific Posters & Publications

Date: October 1, 2026 Time: 12:00 AM ET

AB-101, an Outpatient-Administered Allogeneic NK Cell Therapy, Combined with Rituximab Generates Robust Efficacy Responses in 11 Patients with Sjögren Disease

Date: June 6, 2026 Time: 12:00 AM ET

Robust and Durable Clinical Responses Observed Following Treatment with AB-101, an Allogeneic NK Cell Therapy, Combined with Rituximab in Patients with Severe Rheumatoid Arthritis and Inadequate Response to Multiple Prior Targeted Therapies

Date: June 6, 2026 Time: 12:00 AM ET

AB-101, an Allogeneic NK Cell Therapy, in Combination with Anti-CD20 Monoclonal Antibodies, Consistently Achieves Deep B-cell Depletion Comparable with CAR T Cell Therapies in Patients with Rheumatologic Diseases

Date: June 6, 2026 Time: 12:00 AM ET

AB-101, an Outpatient-Administered Allogeneic NK Cell Therapy, Combined with Rituximab, Generates Robust Clinical Efficacy Responses Comparable with Autologous CAR T in 31 Patients with Rheumatologic Diseases

Date: June 5, 2026 Time: 12:00 AM CT

AB-101, an Allogeneic NK Cell Therapy, Combined with Rituximab was Highly Effective in Severe Sjögren Disease: Experience in First Patient Treated

Date: February 5, 2026 Time: 8:30 PM ET

2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Tandem Meetings 2026

2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Tandem Meetings 2026

Date: May 25, 2023 Time: 5:00 PM ET

American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

American Society of Clinical Oncology (ASCO) 2023

Date: December 11, 2022 Time: 7:00 PM ET

American Society of Hematology (ASH) 64th Annual Meeting

American Society of Hematology (ASH) 2022

Date: November 10, 2022 Time: 9:00 AM ET

Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Society for Immunotherapy of Cancer (SITC) 2022

Showing page 1 of 3

  • 1
  • ...
  • 2
  • ...
  • 3

Archived Presentations

No presentations available right now. Please check back later.

Artivabio

Contact Us

5505 Morehouse Drive, Suite 100
San Diego, California 92121

1.858.267.4467

[email protected]

Twitter opens in a new window Linkedin opens in a new window

Quick Links

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Artiva Biotherapeutics, Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Artiva Biotherapeutics, Inc. to send you the requested Investor Email Alert updates.

* Required

Email Address *

Investor Alert OptionsInvestor Alert Options *

News
Events & Presentations
Quarterly Reports
Annual Reports
SEC Filings

Submit Submit

Unsubscribe

Email Alert Sign Up Confirmation

© 2026 Artiva Biotherapeutics, Inc.

Powered By Q4 Inc. 5.190.1.9 (opens in new window)

Prompts

Artiva Biotherapeutics, Inc. (ticker ARTV), listed in United States.

ETFs Holding Artiva Biotherapeutics, Inc.

ETF Weight in ETF Shares Market value As of
VFMO 0.06% 103,720 $ 1.172M Aug 31, 2026
DFAS 0.00% 8,497 $ 33.648K Nov 12, 2026
DCOR 0.00% 3,029 $ 11.995K Nov 12, 2026
AVSC 0.00% 14,215 $ 56.291K Nov 16, 2026